{
    "clinical_study": {
        "@rank": "4912", 
        "arm_group": [
            {
                "arm_group_label": "BI 1060469 single rising dose part", 
                "arm_group_type": "Experimental", 
                "description": "single rising doses given as tablet"
            }, 
            {
                "arm_group_label": "BI 1060469 food effect part", 
                "arm_group_type": "Experimental", 
                "description": "given as tablet fasted and fed"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the single rising dose part (SRD) is to investigate safety, tolerability,\n      pharmacokinetics, and pharmacodynamics of single rising doses of BI 1060469 in healthy male\n      subjects. The objective of the food effect part (FE) is to investigate the relative\n      bioavailability of BI 1060469 tablets in healthy male subjects in fed or fasted state."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males based upon a complete medical history, including a physical\n             examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and\n             clinical laboratory tests\n\n          2. Age within the range of 18 to 50 years\n\n          3. Body mass index within the range of 18.5 and 29.9 kg/m2\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with good clinical practice (GCP) and local legislation.\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including blood pressure (BP), pulse rate\n             (PR) or electrocardiogram (ECG)) deviating from normal and judged clinically relevant\n             by the investigator. Pulse rate outside the range of 50-90 bpm or blood pressure\n             outside the ranges of 90-140 for systolic and 50-90 mmHg for diastolic blood pressure\n             if confirmed by repeat measurement.\n\n          2. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          3. In the SRD: serum creatinine laboratory value outside the normal range\n\n          4. Glomerular filtration rate (GFR) according to CKD-EPI (Chronic Kidney Disease -\n             Epidemiology Collaboration)-Formula < 60 ml/ min\n\n          5. Current or history of relevant kidney, urinary tract diseases or abnormalities (i.e.\n             nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal\n             failure, infections)\n\n          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          7. Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971502", 
            "org_study_id": "1333.1", 
            "secondary_id": "2013-001475-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 1060469 single rising dose part", 
                "description": "single rising doses", 
                "intervention_name": "Placebo to BI 1060469", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1060469 food effect part", 
                "description": "food effect", 
                "intervention_name": "BI 1060469", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1060469 single rising dose part", 
                "description": "single rising doses", 
                "intervention_name": "BI 1060469", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1333.1.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of BI 1060469 in Healthy Male Volunteers (Single-blind, Placebo-controlled, Randomised, Partly Fixed-sequence, Parallel Group Design) and Effect of Food on the Bioavailability of BI 1060469 (Open-label, Randomised, Two-way Cross-over)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Ministry of Education and Research"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with drug- related adverse events.", 
            "safety_issue": "No", 
            "time_frame": "up to 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971502"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of BI 1060469 in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 1060469 in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of BI 1060469 in plasma over the time interval from 0 up to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}